NOVAMag SHIELD for immediate implants in sockets with buccal bone loss

Evaluation Of The Success Rate of NOVAMag® SHIELD In Two Different Advanced Bone Defects: A Randomized Controlled Trial

Phase 4 Interventional Egas Moniz - Cooperativa de Ensino Superior, CRL · NCT07533110

This trial sees if NOVAMag SHIELD plus a bone graft helps adults with Type 3 extraction sockets and buccal bone dehiscence receive immediate dental implants successfully.

Quick facts

PhasePhase 4
Study typeInterventional
Enrollment40 (estimated)
SexAll
SponsorEgas Moniz - Cooperativa de Ensino Superior, CRL Academic / other
Locations1 site (Almada, Setúbal District)
Trial IDNCT07533110 on ClinicalTrials.gov

What this trial studies

This prospective, controlled observational study will enroll 40 adults needing regenerative treatment in the aesthetic region and stratify them into two groups of 20 based on socket classification (ST3 Subclass B or C). All participants will receive immediate placement of a CE‑approved VEGA® + implant, grafting with cerabone plus mixed with hyaluronic acid, and coverage with the NOVAMag® SHIELD magnesium membrane using the SHIELD technique. Clinical and radiographic outcomes including implant success, bone regeneration, and long‑term suitability for rehabilitation will be recorded to contribute to post‑market surveillance. The protocol includes informed consent, anonymized data handling, and scheduled follow‑up visits to capture safety and performance in routine clinical practice.

Who should consider this trial

Good fit: Adults (≥18) with a tooth in the aesthetic zone indicated for extraction and immediate implant placement and an extraction socket classified as ST3 Subclass B or C are ideal candidates.

Not a fit: Patients who are pregnant, have systemic bone metabolism disorders, active local infection, hypersensitivity to the materials, or sockets that are not ST3 are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the approach could allow immediate implant placement in sockets with moderate to severe buccal bone loss, helping preserve esthetics and simplifying rehabilitation.

How similar studies have performed: Early case series and preclinical data support socket‑shield approaches and resorbable magnesium membranes, but large controlled clinical evidence is still limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 18 years or older;
* Willingness and ability to provide informed consent and accept participation in the study.
* Presence of a tooth indicated for extraction in the aesthetic zone (including premolars);
* Clinical indication for immediate implant placement following tooth extraction;
* Extraction sockets classified as Socket Type 3 (ST3), Subclass B or C, according to the Steigmann (2022) classification;

Exclusion Criteria:

* Pregnancy or lactating women;
* Systemic diseases or conditions known to affect bone metabolism (osteoporosis, uncontrolled diabetes, metabolic bone disorders, chronic corticosteroid therapy, etc.);
* Active infection at the surgical site, including the presence of an acute abscess or other signs of ongoing local infection;
* Hypersensitivity to the biomaterials intended for use in the regenerative procedure.

Where this trial is running

Almada, Setúbal District

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Alveolar Buccal Bone DehiscencesSocket Type 3 Subclass BSocket Type 3 Subclass CBuccal Bone DehiscenceMagnesium MembraneImmediate Implant PlacementSocket Shield Technique
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.